Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker

Journal of Clinical Pathology

Volumn 67, Issue 6, 2014, Pages 520-528

  Lade Keller, Johanne ^a   Riber Hansen, Rikke ^a   Guldberg, Per ^b   Schmidt, Henrik ^a   Hamilton Dutoit, Stephen Jacques ^a   Steiniche, Torben ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; C KIT PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PERK PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; NEVUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STAINING; TISSUE MICROARRAY; ULCER;

CANCER RESEARCH; IMMUNOHISTOCHEMISTRY; MELANOMA; ONCOGENES; SKIN TUMOURS;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901647365     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-202127     Document Type: Article

References (68)

1. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485:502-6.
2. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
3. Koga Y, Pelizzola M, Cheng E, et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 2009;19:1462-70.
4. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58.
5. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS 2007;115:1161-76. (Pubitemid 350179478)
6. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008;21:27-38. (Pubitemid 351421467)
7. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-83. (Pubitemid 27011383)
8. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009;4:551-79.
9. De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl 2):S17-27.
10. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20. (Pubitemid 36068675)
11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
12. Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark 2011;9:267-86.
13. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63. (Pubitemid 41079915)
14. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
15. Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013;32:3009-18.
16. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61.
17. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011;47:2150-7.
18. Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep 2012;14:449-57.
19. Jovanovic B, Krockel D, Linden D, et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol 2008;128:2696-704.
20. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011;24:666-72.
21. Moreau S, Saiag P, Aegerter P, et al. Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 2012;19:4314-21.
22. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003;9:3362-8. (Pubitemid 37082731)
23. Shinozaki M, Fujimoto A, Morton DL, et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004;10:1753-7. (Pubitemid 38435567)
24. Akslen LA, Angelini S, Straume O, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 2005;125:312-17. (Pubitemid 41648165)
25. Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006;16:471-8. (Pubitemid 44934704)
26. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011;17:229-35.
27. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46.
28. Wilmott JS, Menzies AM, Haydu LE, et al. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer 2013;108:924-31.
29. Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2007;2:e236.
30. Essner R, Kuo CT, Wang H, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82:309-16. (Pubitemid 28060247)
31. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-53. (Pubitemid 30305081)
32. Piras F, Perra MT, Murtas D, et al. Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 2008;20:271-7.
33. Vogt T, Zipperer KH, Vogt A, et al. p53-protein and ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997;30:57-63. (Pubitemid 27072449)
34. Karjalainen JM, Eskelinen MJ, Kellokoski JK, et al. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 1999;79:895-902. (Pubitemid 29082123)
35. Florenes VA, Oyjord T, Holm R, et al. TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 1994;69:253-9. (Pubitemid 24046546)
36. Lade-Keller J, Riber-Hansen R, Guldberg P, et al. E- to N-cadherin switch in melanoma is associated with decreased expression of PTEN and cancer progression. Br J Dermatol 2013;169:618-28.
37. de Sa BC, Fugimori ML, Ribeiro Kde C, et al. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas. Melanoma Res 2009;19:135-41.
38. Potti A, Moazzam N, Langness E, et al. Immunohistochemical determination of HER-2/neu, c-kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004;130:80-6. (Pubitemid 38316670)
39. Gonzalez RS, Carlson G, Page AJ, et al. Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome. Am J Clin Pathol 2011;136:74-80.
40. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004;164:193-203. (Pubitemid 38364604)
41. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in chinese patients with melanoma. Clin Cancer Res 2011;17:1684-91.
42. Oba J, Nakahara T, Abe T, et al. Expression of c-kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci 2011;62:116-23.
43. Baldi A, Santini D, Battista T, et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001;83:364-72. (Pubitemid 33027481)
44. Stefanou D, Batistatou A, Zioga A, et al. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol 2004;12:133-8. (Pubitemid 38542485)
45. Janku F, Novotny J, Julis I, et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 2005;15:251-6. (Pubitemid 41127460)
46. Busam KJ, Hedvat C, Pulitzer M, et al. Immunohistochemical analysis of BRAFV600E expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol 2013;37:413-20.
47. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37:61-5.
48. Colomba E, Helias-Rodzewicz Z, Von Deimling A, et al . Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013;15:94-100.
49. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012;123:223-33.
50. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19.
51. Zhuang L, Lee CS, Scolyer RA, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58:1163-9. (Pubitemid 41566460)
52. Houben R, Vetter-Kauczok CS, Ortmann S, et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 2008;128:2003-12. (Pubitemid 352001214)
53. Hussein MR, Haemel AK, Wood GS. P53-related pathways and the molecular pathogenesis of melanoma. Eur J Cancer Prev 2003;12:93-100. (Pubitemid 36543422)
54. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-9. (Pubitemid 41556448)
55. Yamamoto M, Takahashi H. Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch A Pathol Anat Histopathol 1993;422:127-32. (Pubitemid 23100763)
56. McGregor JM, Yu CC, Dublin EA, et al. P53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993;128:606-11. (Pubitemid 23172016)
57. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997;74:535-9. (Pubitemid 27486512)
58. Sparrow LE, English DR, Heenan PJ, et al. Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res 1995;5:387-92.
59. Weiss J, Heine M, Korner B, et al. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995;133:23-31.
60. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, bcl-2 expression, and proliferation. Clin Cancer Res 2005;11:5153-7. (Pubitemid 41003700)
61. Slipicevic A, Holm R, Nguyen MT, et al. Expression of activated akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol 2005;124:528-36. (Pubitemid 41395633)
62. Davies MA, Stemke-Hale K, Lin E, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009;15:7538-46.
63. Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 2003;49:865-72. (Pubitemid 37314875)
64. Phung B, Sun J, Schepsky A, et al. C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS ONE 2011;6:e24064.
65. Salti GI, Manougian T, Farolan M, et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000;60:5012-16.
66. Loercher AE, Tank EM, Delston RB, et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005;168:35-40. (Pubitemid 40111055)
67. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4. (Pubitemid 41117276)
68. Mihic-Probst D, Mnich CD, Oberholzer PA, et al. P16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 2006;118:2262-8.